You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: August 14, 2024

~ Buy the ADVIL ALLERGY SINUS (chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

ADVIL ALLERGY SINUS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Advil Allergy Sinus patents expire, and what generic alternatives are available?

Advil Allergy Sinus is a drug marketed by Haleon Us Holdings and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-four patent family members in eighteen countries.

The generic ingredient in ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Advil Allergy Sinus

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 28, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ADVIL ALLERGY SINUS?
  • What are the global sales for ADVIL ALLERGY SINUS?
  • What is Average Wholesale Price for ADVIL ALLERGY SINUS?
Summary for ADVIL ALLERGY SINUS
International Patents:34
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 3
Patent Applications: 15
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in ADVIL ALLERGY SINUS?ADVIL ALLERGY SINUS excipients list
DailyMed Link:ADVIL ALLERGY SINUS at DailyMed
Drug patent expirations by year for ADVIL ALLERGY SINUS
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ADVIL ALLERGY SINUS
Generic Entry Date for ADVIL ALLERGY SINUS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ADVIL ALLERGY SINUS

ADVIL ALLERGY SINUS is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ADVIL ALLERGY SINUS is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ADVIL ALLERGY SINUS

Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Haleon Us Holdings ADVIL ALLERGY SINUS chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride TABLET;ORAL 021441-001 Dec 19, 2002 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ADVIL ALLERGY SINUS

See the table below for patents covering ADVIL ALLERGY SINUS around the world.

Country Patent Number Title Estimated Expiration
Peru 20081072 COMPOSICIONES DE ANTI-HISTAMINICOS, DESCONGESTIVOS, ANTITUSIVOS Y DROGAS ANTI-INFLAMATORIOS NO ESTEROIDALES ⤷  Sign Up
Spain 2468217 ⤷  Sign Up
Japan 5241228 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.